logo-loader
viewH&T GROUP PLC

Capital Network's Ed Stacey suspects buying opportunity at H&T Group Plc

capital Network analyst Ed Stacey looks through H&T Group PLC's (LON:HAT) interim numbers.

The pawnbroking firm's continued to achieve growth from all of its core revenue streams in the first half of 2018.

''The numbers were strong - 11% PBT growth - that's come from all of the main operating segments .. good spread of the growth drivers''.

''The results also present favourably on the risk metrics - and that's important because it's an aspect that's under appreciated''

Quick facts: H&T GROUP PLC

Price: 382 GBX

LSE:HAT
Market: LSE
Market Cap: £151.79 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of H&T GROUP PLC named herein, including the promotion by the Company of H&T GROUP PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Morning Report: Faron Pharma expands MATINS trial to include ovarian cancer

Headlines from the Proactive UK newsroom. Faron Pharmaceuticals (LON:FARN) is to expand its phase I/II MATINS clinical trial of its Clevegen cancer drug to women with ovarian cancer. Earlier this month, Faron was also given permission to expand the ongoing trial into late-stage colorectal...

22 hours, 37 minutes ago

2 min read